Literature DB >> 18708082

Involvement of MAPKs, NF-kappaB and p300 co-activator in IL-1beta-induced cytosolic phospholipase A2 expression in canine tracheal smooth muscle cells.

Shue-Fen Luo1, Chih-Chung Lin, Hsin-Chieh Chen, Wei-Ning Lin, I-Ta Lee, Chiang-Wen Lee, Li-Der Hsiao, Chuen-Mao Yang.   

Abstract

Cytosolic phospholipase A2 (cPLA2) plays a pivotal role in mediating agonist-induced arachidonic acid release for prostaglandin (PG) synthesis during stimulation with interleukin-1beta (IL-1beta). However, the mechanisms underlying IL-1beta-induced cPLA2 expression and PGE2 synthesis by canine tracheal smooth muscle cells (CTSMCs) have not been defined. IL-1beta induced cPLA2 protein and mRNA expression, PGE2 production, and phosphorylation of p42/p44 MAPK, p38 MAPK (ATF2), and JNK (c-Jun) in a time- and concentration-dependent manner, determined by Western blotting, RT-PCR, and ELISA, which was attenuated by the inhibitors of MEK1/2 (U0126), p38 MAPK (SB202190), and JNK (SP600125), or transfection with dominant negative mutants of MEK1/2, p38, and JNK, respectively. Furthermore, IL-1beta-induced cPLA2 expression and PGE2 synthesis was inhibited by a selective NF-kappaB inhibitor (helenalin) or transfection with dominant negative mutants of NF-kappaB inducing kinase (NIK), IkappaB kinase (IKK)-alpha, and IKK-beta. Consistently, IL-1beta stimulated both IkappaB-alpha degradation and NF-kappaB translocation into nucleus in these cells. NF-kappaB translocation was blocked by helenalin, but not by U0126, SB202190, and SP600125. MAPKs together with NF-kappaB-activated p300 recruited to cPLA2 promoter thus facilitating the binding of NF-kappaB to cPLA2 promoter region and expression of cPLA2 mRNA. IL-1beta-induced cPLA2 expression and PGE2 production was inhibited by actinomycin D and cycloheximide, indicating the involvement of transcriptional and translational events in these responses. These results suggest that in CTSMCs, IL-1beta-induced cPLA2 expression and PGE2 synthesis was independently mediated through activation of MAPKs and NF-kappaB pathways and was connected to p300 recruitment and activation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18708082     DOI: 10.1016/j.taap.2008.07.019

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  6 in total

1.  Novel curcumin analog C66 prevents diabetic nephropathy via JNK pathway with the involvement of p300/CBP-mediated histone acetylation.

Authors:  Yangwei Wang; Yonggang Wang; Manyu Luo; Hao Wu; Lili Kong; Ying Xin; Wenpeng Cui; Yunjie Zhao; Jingying Wang; Guang Liang; Lining Miao; Lu Cai
Journal:  Biochim Biophys Acta       Date:  2014-11-11

2.  Caloric restriction: powerful protection for the aging heart and vasculature.

Authors:  Edward P Weiss; Luigi Fontana
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-08-12       Impact factor: 4.733

Review 3.  Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets.

Authors:  Bei Wang; Lujin Wu; Jing Chen; Lingli Dong; Chen Chen; Zheng Wen; Jiong Hu; Ingrid Fleming; Dao Wen Wang
Journal:  Signal Transduct Target Ther       Date:  2021-02-26

4.  MEKK1-MKK4-JNK-AP1 pathway negatively regulates Rgs4 expression in colonic smooth muscle cells.

Authors:  Yonggang Zhang; Fang Li; Shu Liu; Hong Wang; Sunila Mahavadi; Karnam S Murthy; Kamel Khalili; Wenhui Hu
Journal:  PLoS One       Date:  2012-04-24       Impact factor: 3.240

5.  The step further to understand the role of cytosolic phospholipase A2 alpha and group X secretory phospholipase A2 in allergic inflammation: pilot study.

Authors:  Ewa Pniewska; Milena Sokolowska; Izabela Kupryś-Lipińska; Monika Przybek; Piotr Kuna; Rafal Pawliczak
Journal:  Biomed Res Int       Date:  2014-08-27       Impact factor: 3.411

Review 6.  Effects of Antimalarial Drugs on Neuroinflammation-Potential Use for Treatment of COVID-19-Related Neurologic Complications.

Authors:  Wei-Yi Ong; Mei-Lin Go; De-Yun Wang; Irwin Kee-Mun Cheah; Barry Halliwell
Journal:  Mol Neurobiol       Date:  2020-09-08       Impact factor: 5.590

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.